Drug: Rapamycine

What It Is

Rapamycin is a compound first isolated in the twentieth century from a soil bacterium found on Easter Island. Its name comes from the island's local name, Rapa Nui. As the drug sirolimus, it has been used in medicine for decades. Its main job there is to suppress the immune system after an organ transplant, so the body does not reject the new organ. It also coats the stents that hold coronary arteries open. Two close relatives, everolimus and temsirolimus, treat certain cancers and the rare disease tuberous sclerosis.

Rapamycin became the most discussed molecule in aging research for a reason separate from all of that. It acts on a growth-control pathway called mTOR, and dialing that pathway down is the intervention the whole longevity case rests on. That has produced a large and growing off-label use: people take rapamycin hoping to slow their own aging, well ahead of any human trial.

Anatomy

1The mTOR pathway

mTOR, the mechanistic target of rapamycin, is a master growth switch inside every cell. It senses nutrients and growth signals and, when they are plentiful, drives the cell to build proteins and grow while holding back cellular recycling. Turning mTOR down slows growth and steps up autophagy, the process that clears out worn-out cellular parts. This is the pathway the whole longevity case runs through.

2Sirolimus, the original drug

Sirolimus is rapamycin as a licensed medicine. It is given orally to prevent kidney transplant rejection and to treat the rare lung disease lymphangioleiomyomatosis, and it coats drug-eluting cardiac stents. It is the form with the longest human safety record, gathered mostly in transplant patients taking it continuously at doses set to suppress the immune system.

3Everolimus and the analogues

Everolimus and temsirolimus are chemical relatives of rapamycin, the class often called rapalogs. Everolimus is approved for several cancers, for tuberous sclerosis, and in transplant medicine. In aging research the low-dose, short-course use of everolimus is what produced the human immune findings, at doses well below those used to prevent transplant rejection.

How It Works

Rapamycin inhibits mTOR complex 1, the branch of the mTOR pathway that governs cell growth. It acts indirectly. The drug first binds a small intracellular protein called FKBP12. That pair then latches onto mTOR complex 1 and shuts much of its activity down.

When mTOR complex 1 is active, the cell responds as if nutrients are abundant: it builds proteins, grows, and slows recycling. Inhibiting the complex reverses that: the cell lowers its building and switches on autophagy, the housekeeping process that breaks down and recycles damaged parts. The result reproduces much of the cellular state that fasting produces.

That link is why aging biology keeps returning to the drug. Nutrient sensing is one of the recognized hallmarks of aging, and mTOR is its central node. A drug that turns the node down is a direct test of the idea that dialing back growth signaling slows aging. For where mTOR fits among the other drivers, see the biology of aging.

Prolonged or higher-dose rapamycin also disturbs a second complex, mTOR complex 2. That second effect is tied to the drug's influence on blood sugar and insulin. It is the mechanism behind the metabolic risks listed later.

What It Does

The animal record is the strongest in longevity research. In the National Institute on Aging Interventions Testing Program, rapamycin extended the lifespan of genetically diverse mice. The program runs each compound at three separate laboratories to screen out fluke results, and the rapamycin result held up to replication. It worked even when treatment began at roughly the human equivalent of age 60. No other longevity molecule has an animal record this consistent, which is why the mouse findings sit at the top of the ladder below. Still, a lifespan gain in mice is a reason to study the drug in people. It is not yet proof of anything in humans.

The human evidence sits lower. It measures immunity and feasibility, and it has not measured lifespan at all. No completed trial has tested whether rapamycin extends human life or healthspan. The signals that exist are narrow immune findings in adults over 65, measured over weeks to a year. One large phase-3 trial of the mTOR inhibitor RTB101, given on its own, missed its main infection endpoint. So the human evidence is still preliminary. Trials of physical function in healthy people are small and early.

Most of what is known about rapamycin's side effects comes from the approved uses. There, sirolimus, everolimus, and temsirolimus are dosed continuously, at levels set to suppress the immune system or hold back a tumor. None of those licensed indications is aging.

The Research & Studies

Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.

How it works

Rapamycin inhibits mTORC1, mimicking mild fasting and switching on autophagyStrong · mixed

In plain terms

Rapamycin turns down mTOR, the master switch a cell uses to sense nutrients and balance growth against recycling. Turning it down mimics mild fasting and steps up autophagy, the recycling of worn-out parts.

In detail

Rapamycin (sirolimus) forms a complex with the 12 kDa FK506-binding protein (FKBP12) that binds and inhibits mTOR complex 1. mTORC1 integrates signals from amino acids, growth factors and energy status to drive ribosome biogenesis, protein and lipid synthesis, and cell growth, and it suppresses macroautophagy. Inhibiting mTORC1 therefore lowers anabolic activity and de-represses autophagy, reproducing much of the cellular state that nutrient scarcity and caloric restriction produce. Prolonged or higher-dose exposure also affects the second complex, mTORC2, which is relevant to the metabolic effects seen with the drug.

The study · 1

Saxton and Sabatini, mTOR Signaling in Growth, Metabolism, and Disease · Cell 2017;169(2):361-371

Respiratory Infection

Un inhibiteur de mTOR à faible dose a réduit les infections respiratoires chez les personnes âgées au cours de l'année suivanteModerate

In plain terms

Dans un essai de suivi plus large, un inhibiteur de mTOR à faible dose a réduit le nombre d'infections respiratoires chez les personnes âgées sur une année. C'est le signal humain le plus fort indiquant que réduire l'activité de mTOR peut soutenir la fonction immunitaire avec l'âge.

In detail

Mannick et ses collègues (2018) ont randomisé 264 personnes âgées pour recevoir des combinaisons de l'inhibiteur de mTOR RTB101 et d'everolimus, ou un placebo, et ont suivi les infections des voies respiratoires sur une année. Le schéma combinant de faibles doses des deux médicaments a réduit le taux d'infections respiratoires confirmées en laboratoire et a été associé à une signature génique antivirale régulée à la hausse, étendant la découverte vaccinale précédente à un critère clinique d'infection.

The study · 1

Mannick et al., TORC1 inhibition enhances immune function and reduces infections in the elderly · Sci Transl Med 2018;10(449):eaaq1564

Blood Sugar

La rapamycine chronique a causé une résistance à l'insuline chez la souris en perturbant mTORC2Moderate · risk

In plain terms

La rapamycine à long terme peut provoquer une résistance à l'insuline, et chez la souris cela provient de l'atteinte d'un second complexe mTOR. Cela suggère que l'inconvénient métabolique et le bénéfice de longévité pourraient emprunter des branches différentes de la voie.

In detail

Lamming et ses collègues (2012) ont montré que la rapamycine chronique chez la souris perturbe le complexe mTOR 2 (mTORC2) en plus de mTORC1, et que la perte de signalisation mTORC2 dans le foie entraîne l'intolérance au glucose et la résistance à l'insuline observées avec le médicament. Comme la prolongation de la durée de vie est attribuée principalement à l'inhibition de mTORC1, ce travail a soulevé la possibilité que le coût métabolique et le bénéfice de longévité soient, au moins en principe, dissociables.

The study · 1

Lamming et al., Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity · Science 2012;335(6076):1638-1643

La rapamycine a laissé les souris intolérantes au glucose tout en restant sensibles à l'insulineModerate · mixed

In plain terms

L'effet de la rapamycine sur la glycémie chez la souris est mitigé : elle aggrave la gestion du glucose selon un test tout en préservant la sensibilité à l'insuline selon un autre. Le tableau métabolique est plus complexe qu'une simple étiquette.

In detail

Lamming et ses collègues (2013) ont constaté que des souris jeunes et âgées, génétiquement hétérogènes, nourries à la rapamycine étaient intolérantes au glucose lors d'une épreuve de charge en glucose tout en restant sensibles à l'insuline, une dissociation qui ne correspond pas au schéma habituel du diabète de type 2. Cette découverte affine la question métabolique sans l'écarter, car l'intolérance au glucose, l'élévation des triglycérides et du cholestérol sont également documentées chez les personnes prenant ce médicament pour une greffe d'organe.

The study · 1

Lamming et al., Young and old genetically heterogeneous HET3 mice on a rapamycin diet are glucose intolerant but insulin sensitive · Aging Cell 2013;12(4):712-718

Immune Function

Six semaines d'un inhibiteur de mTOR ont augmenté d'environ 20 % la réponse en anticorps au vaccin contre la grippe chez les personnes âgéesEmerging

In plain terms

Une courte cure d'un inhibiteur de mTOR a amélioré la réponse des personnes âgées au vaccin contre la grippe. Il s'agit d'une découverte immunitaire humaine limitée, non d'une preuve concernant la durée de vie.

In detail

Mannick et ses collègues (2014) ont randomisé 218 adultes âgés de 65 ans et plus pour recevoir de faibles doses de l'analogue de la rapamycine everolimus ou un placebo pendant six semaines avant la vaccination antigrippale saisonnière. L'everolimus à faible dose a amélioré la réponse en anticorps au vaccin d'environ 20 % et réduit la proportion de sous-populations de cellules immunitaires épuisées et sénescentes, suggérant que l'inhibition de mTOR peut partiellement inverser certains aspects du vieillissement immunitaire. Les doses étaient plus faibles et administrées sur une période plus courte que celles utilisées pour prévenir le rejet de greffe.

The study · 1

Mannick et al., mTOR inhibition improves immune function in the elderly · Sci Transl Med 2014;6(268):268ra179

Longevity And Mortality

Rapamycin started late raised mouse lifespan about 9% in males and 14% in femalesPreliminary

In plain terms

Rapamycin is the most reliable drug known for extending lifespan in mice, and it works even when started in old age. The finding has been repeated in a rigorous multi-site program, which is why it is the flagship animal result.

In detail

Harrison and colleagues (2009) reported that rapamycin fed to genetically heterogeneous mice starting at 600 days of age extended median and maximal lifespan in both sexes, a striking result because the treatment began late in life. Miller and colleagues (2011) confirmed lifespan extension with rapamycin in the same multi-site Interventions Testing Program while resveratrol and simvastatin did not extend life, strengthening the finding through independent replication. The Interventions Testing Program tests compounds at three sites in a genetically diverse mouse population specifically to reduce false positives.

The studies · 2

Harrison et al., Rapamycin fed late in life extends lifespan in genetically heterogeneous mice · Nature 2009;460(7253):392-395

Miller et al., Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice · J Gerontol A Biol Sci Med Sci 2011;66(2):191-201

Une dose trois fois plus élevée a prolongé la durée de vie de la souris d'environ 23 % chez les mâles et 26 % chez les femellesPreliminary

In plain terms

L'effet du rapamycine sur la durée de vie chez la souris s'accentue à doses plus élevées et diffère entre mâles et femelles, ce qui montre que le bénéfice est lié à la dose et n'équivaut pas simplement à une restriction alimentaire.

In detail

Miller et ses collègues (2014) ont testé des doses plus élevées de rapamycine chez des souris génétiquement hétérogènes et ont observé des gains de durée de vie plus importants qu'à la dose initiale, avec une réponse à la dose claire et des différences constantes entre sexes dans l'ampleur de l'effet. Les auteurs ont également rapporté que les changements métaboliques accompagnant la rapamycine différaient de ceux produits par la restriction alimentaire, indiquant que les deux interventions prolongent la vie par des voies au moins en partie distinctes.

The study · 1

Miller et al., Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction · Aging Cell 2014;13(3):468-477

Cognition

La rapamycine chronique a amélioré l'apprentissage et diminué les comportements de type anxieux chez la sourisPreliminary

In plain terms

Chez la souris, la rapamycine à long terme a amélioré l'apprentissage et réduit les comportements de type anxieux. Il s'agit d'un signal animal précoce pour le cerveau, non d'un effet démontré chez l'humain.

In detail

Halloran et ses collègues (2012) ont administré à des souris de la rapamycine chronique tout au long de la vie et ont constaté des améliorations aux tests d'apprentissage et de mémoire, accompagnées d'une réduction des comportements de type anxieux et dépressif, ainsi que des taux cérébraux plus élevés de plusieurs neurotransmetteurs. Ce travail constitue une piste mécanistique précoce sur les effets de l'inhibition de mTOR sur le cerveau vieillissant, et non une preuve de bénéfice cognitif chez l'humain.

The study · 1

Halloran et al., Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice · Neuroscience 2012;223:102-113

Muscle And Strength

Huit semaines de rapamycine n'ont montré aucun gain net de performance physique chez des personnes âgées en bonne santéPreliminary · no effect

In plain terms

Un petit essai humain de courte durée a montré que la rapamycine était bien tolérée chez des personnes âgées en bonne santé, mais sans amélioration nette de la fonction physique. Les essais de longévité humaine avec critères de fonction physique n'en sont qu'à leurs débuts.

In detail

Kraig et ses collègues (2018) ont randomisé 25 personnes âgées en bonne santé pour recevoir huit semaines de rapamycine ou de placebo afin de tester la faisabilité et l'innocuité, en suivant des mesures immunitaires, de performance physique et cognitives. Le médicament a été bien toléré sans événement indésirable grave, et aucun changement net n'a été observé dans la performance physique, la cognition ou la plupart des mesures immunitaires au cours de cette étude courte et de petite taille, conçue pour établir la faisabilité, non pour détecter un effet. Le seul signal biologique constant fut des diminutions statistiquement significatives de plusieurs mesures liées aux globules rouges, dont l'hémoglobine, l'hématocrite et le nombre de globules rouges, jugées par les auteurs non cliniquement significatives sur cette courte étude. Des efforts hors indication plus vastes, tels que l'essai PEARL, qui utilise des critères de fonction physique, restent préliminaires.

The study · 1

Kraig et al., A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort · Exp Gerontol 2018;105:53-69

The Off-Label Gap

Between the strong animal data and the thin human data sits a large off-label experiment. Most users take rapamycin on an intermittent schedule. Transplant medicine, by contrast, uses continuous dosing. The off-label idea is that spaced doses might keep the growth-slowing effect while easing the load on the immune system. That reasoning is a hypothesis drawn from animal work and pharmacology. No completed human longevity trial has confirmed it.

The human function data is small and short. A feasibility trial gave healthy older adults an eight-week course and found it tolerable. Over that span it produced no clear change in physical performance, cognition, or most immune measures. Its one consistent laboratory signal was a statistically significant drop in several red-cell measures, including hemoglobin, hematocrit, and red blood cell count. The investigators judged that drop not clinically significant over the short trial. Larger efforts such as the PEARL trial, which uses physical-function endpoints, are still preliminary.

Rapamycin is a prescription immunosuppressant, not a supplement, and no completed human trial establishes a safe or effective dose for slowing aging in a healthy person.

The animal case is strong, the human aging case is early, and the best schedule for a healthy person is unknown. The risks are documented in the Cautions below.

Go Deeper

• The biology of aging: where rapamycin and mTOR sit among the hallmarks of aging, and how to read an animal drug result against the human evidence.
• Autophagy: the cellular recycling process rapamycin switches on by inhibiting mTOR, and the mechanism much of the longevity case runs through.
• Peptides: another category where a few approved drugs sit alongside a large off-label market, and how to keep the two apart.
• IV therapy and NAD: a neighboring anti-aging pitch, and the same distinction between moving a marker and changing an outcome.

The Chinese Medicine View

Rapamycin is a modern isolate, so no classical Chinese entry exists for it. No historical text assigns it a channel, a temperature, or a flavor, and no traditional formula contains it. Nothing suggests any herb or formula reproduces what rapamycin does.

The tradition does reason about the territory the drug acts on. In cellular terms, rapamycin mimics a fasting signal: it lowers building in a well-fed cell and clears out what is worn. That sits close to a deep theme in Chinese medicine, the idea in Yang Sheng, the cultivation of life, that moderation and restraint conserve the body's reserves. Classical counsel to stop eating before fullness, and the long practice of periodic simplicity in eating, reach the same place by observation. Nutrient-sensing biology points the same way: constant abundance and constant growth signaling appear to accelerate aging.

The tradition also holds a caution that fits here. Tonifying, or building the body up, is appropriate only when there is a true deficiency and the person can assimilate what is given. Push past that, and the same effort depletes the body instead of restoring it. A drug that suppresses the immune system and disturbs the transformation of nourishment is, in that framing, a powerful intervention with a cost.

The drug stands or falls on the trials. The animal trials are numerous; trials in healthy humans are almost none.

Cautions

Everything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.

Aux doses thérapeutiques, le sirolimus a couramment causé des ulcères buccaux, une augmentation du cholestérol et de la diarrhée

McCormack et ses collègues (2011) ont randomisé 89 femmes atteintes de lymphangioléiomyomatose pour recevoir du sirolimus ou un placebo pendant un an. Le sirolimus a stabilisé la fonction pulmonaire pendant le traitement, et l'essai a documenté son profil d'effets indésirables : mucosite (ulcères buccaux), effets gastro-intestinaux tels que diarrhée et nausées, éruption acnéiforme, hypercholestérolémie et œdème périphérique sont survenus plus souvent qu'avec le placebo. Le bénéfice sur la fonction pulmonaire a été perdu après l'arrêt du médicament, soulignant que ces effets accompagnent un dosage thérapeutique continu.McCormack et al., Efficacy and safety of sirolimus in lymphangioleiomyomatosis

Prescription drug, immune-suppressing

Rapamycin is a prescription drug whose primary action is to suppress the immune system. At the doses used in transplant medicine it lowers immune defenses enough to raise the risk of infections, including serious ones, and it requires blood-level monitoring and medical oversight. Whatever the longevity hopes attached to it, it belongs in the hands of a clinician who can weigh that risk for a given person.

Infection risk

Because it dampens immune function, rapamycin can make infections more likely and harder to clear. This is the central trade-off of the drug and the reason the aging research uses lower, spaced doses in the hope of reducing it. Whether intermittent dosing avoids meaningful immunosuppression in a healthy person is not established.

Mouth ulcers and impaired wound healing

Mouth ulcers, or mucositis, are among the most common side effects. Rapamycin also slows wound healing, so surgeons often pause it around operations. Anyone facing surgery or dealing with a wound needs a clinician to manage the drug, not a schedule found online.

Effects on blood sugar and lipids

Rapamycin can raise cholesterol and triglycerides and can worsen glucose handling. In animals the metabolic picture is mixed, and in transplant patients these changes are well documented. They are part of the risk that any longevity use has to account for.

Drug interactions

Rapamycin is processed by liver enzymes that many other drugs and even grapefruit affect, so its blood levels can swing up or down when combined with common medications. This is one more reason its use requires a prescriber who knows the full medication list, not self-management.

Not a do-it-yourself longevity drug

If rapamycin interests you, the responsible step is a clinician who can order blood-level monitoring and weigh the risks for you. No home protocol substitutes for that oversight while the aging trials are unfinished.

Start slow, be smart, read the research, and consult a professional if you have any concerns. This is here to inform your choice, not make it for you.

Common Questions

Does rapamycin actually extend lifespan?

Living longer and staying healthy longer are different questions, and rapamycin's mouse data speaks mainly to the first. No human study has followed people long enough to measure either one directly. That is why aging research leans on shorter-term markers instead of years of life, and why a confident human lifespan claim is not yet possible.

Is rapamycin approved for anything?

Yes, for several specific diseases, all covered above. What matters for aging is what is missing from that list: no regulator has approved rapamycin, or any drug, for aging itself. Every longevity use therefore falls outside the label. That gap is the whole reason the practice is called off-label.

Why do some people take rapamycin off-label for aging?

The reasoning is covered above. Off-label has a specific legal meaning: a clinician may legally prescribe an approved drug for a purpose it was never approved for, at their own discretion. That is how rapamycin reaches healthy people while the aging trials are still unfinished. It also means the prescriber and the patient, not a regulator, carry the evidence burden.

What are the main risks of rapamycin?

The specific risks are listed in the Cautions above. The deciding factor is supervision. In its approved uses rapamycin comes with blood-level testing and a clinician watching for infection; someone self-sourcing it for aging has neither. The same molecule therefore carries a different real-world risk depending on whether anyone is monitoring it.

Can a Chinese herb or formula do what rapamycin does?

No. No herb or formula has been shown to inhibit mTOR the way rapamycin does. TheOverlap is a shared idea about restraint, not a shared mechanism. Fasting and dietary restraint engage the same mTOR pathway at no cost, and both are open to anyone.